Navigation Links
New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Date:12/10/2007

ressure.

LEVITRA is not recommended for patients with uncontrolled hypertension (>170/110 mmHg).

In men for whom sexual activity is not recommended because of their underlying cardiovascular status, any treatment for erectile dysfunction, including LEVITRA, generally should not be used.

In patients taking certain CYP3A4 inhibitors (eg, ritonavir, indinavir, saquinavir, atazanavir, ketoconazole, itraconazole, erythromycin, and clarithromycin), lower doses of LEVITRA are recommended, and time between doses of LEVITRA may need to be extended. See prescribing information for LEVITRA for dosing guidance.

In clinical trials, the most commonly reported adverse events with LEVITRA were headache, flushing, and rhinitis. Adverse events were generally transient.

Nonarteritic anterior ischemic optic neuropathy (NAION) has been reported rarely postmarketing in temporal relationship with the use of PDE5 inhibitors, including LEVITRA. Sudden loss of hearing, sometimes with tinnitus and dizziness, also has been reported rarely in temporal association with the use of PDE5 inhibitors, including LEVITRA. It is not possible to determine if these events are related to PDE5 inhibitors or to other factors. Physicians should advise patients to stop use of PDE5 inhibitors, including LEVITRA, and seek prompt medical attention in the event of sudden loss of vision or hearing.

The recommended starting dose of LEVITRA is 10 mg. Titrate up to 20 mg or down to 5 mg based on efficacy and side effects.
The maximum recommended dosing frequency is once daily.

LEVITRA is available in 2.5-mg, 5-mg, 10-mg and 20-mg tablets.

For Prescribing Information please visit http://www.levitra.com.

About GlaxoSmithKline

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling peop
'/>"/>

SOURCE Schering-Plough
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  New York College of Health Professions announces ... portfolio with U.S. Patent #8,996,098 donated by its Chairman ... a surgical instrument that allows surgeons to view and ... in the traditional format of a slide that is ... during surgery, thus providing the surgeon real time analysis ...
(Date:4/1/2015)... ASPEN, Colo. , April 1, 2015  Astellas ... (CKF), is pleased to sponsor the second annual Bounce ... award, which will recognize two transplant recipients who exhibit ... a career accomplishment, participation in a sport or hobby, ... loved ones. "The Bounce Back Award ...
(Date:4/1/2015)... 2015  The fairness of the proposed acquisition of ... Pharmaceutical Industries ("Teva") is being investigated by WeissLaw LLP, ... investigation focuses on possible breaches of fiduciary duty and ... of ASPX for agreeing to sell the Company to ... definitive agreement for Teva to acquire ASPX in a ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 3WeissLaw LLP: Auspex Pharmaceuticals Inc. Acquisition By Teva Pharmaceutical Industries May Not Be In The Best Interest of ASPX Shareholders 2
... Recent Highlights: Qutenza ® (capsaicin) ... adoption by large US institutions; 238 hospitals purchased as of 4Q10, ... Q4 2010 revenue totaled $2.3 million including $0.5 million U.S. Qutenza ... in 17 countries at December 31, 2010 NGX-1998 Phase 2 ...
... March 30, 2011 Rochester Medical Corporation (Nasdaq: ... BioSciences N.V. today approved the previously announced sale of ... subsidiary to Rochester Medical Corporation. Rochester Medical ... and under the terms of the Share Purchase Agreement ...
Cached Medicine Technology:NeurogesX Reports Fourth Quarter and Year-End 2010 Results 2NeurogesX Reports Fourth Quarter and Year-End 2010 Results 3NeurogesX Reports Fourth Quarter and Year-End 2010 Results 4NeurogesX Reports Fourth Quarter and Year-End 2010 Results 5NeurogesX Reports Fourth Quarter and Year-End 2010 Results 6NeurogesX Reports Fourth Quarter and Year-End 2010 Results 7NeurogesX Reports Fourth Quarter and Year-End 2010 Results 8NeurogesX Reports Fourth Quarter and Year-End 2010 Results 9Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation 2
(Date:4/1/2015)... This year for Oral Cancer Awareness Month, ... for an Open House to offer complimentary oral cancer screenings ... p.m. An appointment is required and can be secured by ... 212-689-0024. In addition, Herald Square Dental and The Denture Center ... of April at the reduced cost of $39 (regularly $78). ...
(Date:4/1/2015)... Arroyo Grande, CA, March 24, 2015 (PRWEB) April 01, 2015 ... is considered by many, the most extreme jungle adventure you ... to as many as 23 days. Endorsed by the Philippine ... , ”Many people have visited the rainforest, but very few ... said Johan Bergman, Chief Adventure Officer. , Armed with nothing ...
(Date:4/1/2015)... New York (PRWEB) April 01, 2015 ... hundreds of Risperdal lawsuits ( http://www.risperdallawsuit2014.com/ ) has ... the calendar for the Philadelphia Court of Common Pleas, ... Room 206, City Hall. Court records indicate that the ... filed on behalf of Risperdal users who experienced gynecomastia ...
(Date:4/1/2015)... 2015 SCI Solutions , the ... today announced that CEO Joel French will be a ... & Exhibition in Chicago, April 12-16, 2015. French ... Provider Care Coordination Strategies ” with Northeast Georgia Health ... CDT. More than 38,000 healthcare industry professionals are expected ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 OSF Saint ... OSF Healthcare System , was welcomed into the Ministry ... officiated by Msgr. Paul E. Showalter, vicar general of ... Blessing and Dedication culminated a nearly year-long transition process ... OSF HealthCare hospital. Speakers for the morning ceremony included ...
Breaking Medicine News(10 mins):Health News:Herald Square Dental Celebrates Oral Cancer Awareness Month 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3
... spread and prevention of the superbug Clostridium difficile is ... of Medical Microbiology. These findings will play a crucial ... against a sometimes deadly pathogen. , Clostridium difficile is ... hospitals. It can cause a serious hospital-acquired infection when ...
... normal version of particular gene respond well to targeted ... cancer patients who have the normal version of a ... combination treatment that includes adding the targeted therapy Erbitux ... have the normal, or "wild-type" form of the gene, ...
... prevent malignancies, study suggests , , SUNDAY, June 1 (HealthDay ... day have value in helping to prevent lung cancer. ... cox-2 inhibitor on the U.S. market, may reduce levels ... The team presented its findings Sunday at the American ...
... the most common types, study says , , SUNDAY, June 1 ... were children or adolescents are much more likely than other ... , Hodgkin disease (HD), a cancer of the lymph nodes, ... survivors may be at future risk of developing second cancers ...
... the first time suggests that people suffering from hay ... worsening of their nasal passage functioning, depending on how ... study published in the June 2008 edition of Otolaryngology ... by researchers in Italy, discovered that in 100 patients ...
... Anti-angiogenesis drug prolonged progression-free survival, study finds , , ... drug Avastin to chemotherapy lengthened progression-free survival in ... , Previous studies have found that adding Avastin ... women with advanced breast cancer actually doubled progression-free ...
Cached Medicine News:Health News:Advances in C. difficile research 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 2Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 3Health News:Young Hodgkin Survivors Face Later Risk of Second Cancers 2Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 3
... HER2 FISH pharmDx Kit is a direct ... to quantitatively determine HER2 gene amplification in ... amplification is determined from the ratio between ... of the HER2 gene probe (red signals) ...
... only HER-2 assessment test approved by the ... three claims: prognosis, adriamycin-based chemotherapy selection and ... is the only FISH-based DNA probe HER-2 ... as an appropriate test to aid in ...
... Innovators in Anesthesia and Respiratory Products, ... quality medical devices for Anesthesia and Respiratory ... manufacture products that enhance the clinician's ability ... close attention to the bottom line. , ...
... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
Medicine Products: